floatz

floatz is an AI-driven drug discovery platform that provides end-to-end R&D services to accelerate therapeutic development by translating complex biomedical data into validated targets and strategic intelligence. It offers novel target identification, target validation and prioritization, mechanism and pathway elucidation, preclinical candidate assessment, and biomarker and clinical intelligence. The platform integrates vast biomedical data sources using AI to uncover non-obvious patterns, with PhD-level experts curating the insights to produce decision-ready reports. This combination of AI and expert curation helps biotech and pharmaceutical companies de-risk pipelines and speed up development timelines. floatz partners with ETH AI Center and Microsoft for Startups, positioning itself as a scientifically rigorous and collaborative player in biotech AI.

AIBiomedical DataBiotechDrug DiscoveryPharmaceuticalR&DTarget IdentificationTarget Validationfloatz.ai

floatz

AIBiomedical DataBiotechDrug DiscoveryPharmaceuticalR&DTarget IdentificationTarget Validationfloatz.ai

HQZürich, CH

Team Size4

Open Jobs2

Total Funding-

Latest FundraiseUnknown

Join the Team

Strategic Deal Partner (Biotech Hedge Funds)

RemoteNew York, NY, US

Remote • New York, NY, US

Teeming tracks opportunities at over 24,000 AI startups, then works with you to find (and land) the one you'll love.

Data Scientist

Full-timeNovi Sad, RS

Full-time • Novi Sad, RS

AI Researcher

Part-timeRotterdam, NL

Part-time • Rotterdam, NL

Product Designer

InternshipJerusalem

Internship • Jerusalem

Frontend Developer

ContractUtrecht, NL

Contract • Utrecht, NL

Technical Writer

ContractSan Francisco, US

Contract • San Francisco, US

Software Engineer

ContractLondon, GB

Contract • London, GB

Title: Strategic Deal Partner (Biotech Hedge Funds)

Compensation: 20–25% Uncapped Commission + Optional Advisory Equity

Structure: Independent Contractor / Introducer Agreement

Opportunity: Sell Risk Visibility, Not Software.

floatz uses AI to stress-test the science behind biotech programs. Our platform surfaced major toxicity red flags in Rubius ~2 years before its $200M+ collapse.

We’re expanding on the buy-side and seeking a Deal Partner to originate introductions into biotech-focused hedge funds.

This is an access-driven role. Not volume sales.

Who You Are

You’re already connected to PMs or pod leads. Likely backgrounds:

Expert Networks (GLG/AlphaSights): Ready to monetize real influence.
Institutional / PB / Research Sales: Fluent in Soft Dollars (28e).
Cap Intro / HF Connector: Your intros get taken.

You understand:

binary events • readout risk • drawdowns • scientific failure risk • pass-through expenses

The Role

Your job: Book a 20-min “Risk Review” with a PM holding a biotech ticker.
Our job: Run the diligence, present risks, close the engagement.

You focus on origination. Not long cycles.

The Deal

Commission: 20–25% of the first engagement (uncapped). Most initial engagements fall in the $48.5k–$145k range, translating to $10k–$36k+ per introduction .
Equity: Optional micro-advisory equity for consistent high-impact originators

DO NOT APPLY IF...

⛔ You want a base salary

⛔ You’ve never sold to hedge funds

⛔ You struggle with high-level biotech or investment concepts

⛔ You rely on long, multi-touch SaaS sales sequences

This is for people who can create trust-based access to decision-makers.